



BAB VI
DAFTAR PUSTAKA



- Bambang. Karsinoma Nasopharynx. Cerm Dun Ked 1977;9:86-88.
- Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM. Molecular Diversity of Epstein-Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European Subjects. *J Infect Dis* 2004;190:53-62.
- Fieser TM, Tainer JA, Geysen HM, Houghten RA, Lerner RA. Influence of protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix. *Proc Natl Acad Sci U S A* 1987; 84(23): 8568-8572.
- Harijadi, Haryanto A, Wijayanti N. Tipe Epstein-Barr Virus Berdasarkan Analisis Molekuler Gena EBNA Pada Penderita Nasopharyngeal Carcinoma Di Yogyakarta. *Berita Ked Masyarakat* 2000;16(1):3-8.
- Harijanto M, Tranggana S, Daud D. Nasopharyngeal Carcinoma. *J Med Nusantara* 1996;17(3):130-134.
- Hu L, Troyanovsky B, Zhang X, Trivedi P, Ernberg I, Klein G. Differences in the Immunogenicity of Latent Membrane Protein 1 (LMP1) Encoded by Epstein-Barr Virus Genomes Derived from LMP1-positive and -negative Nasopharyngeal Carcinoma. *Cancer Research* 2000;60:5589-5593.
- Janeway CA, Travers P, Walport M, Shlomchik MJ. *Immunobiology 5th ed, The Immune System In Health and Disease*. New York: Garland Publishing. 2001
- Li HP, Chang YS. Epstein-Barr virus Latent Membrane Protein 1 : Structure and Function. *J Biomed Sci* 2003;10:490-504.



- Meij P, Vervoort MBHJ, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJLM, Middeldorp JM. Restricted Low-Level Human Antibody Responses against Epstein-Barr virus (EBV)-Encoded Latent Membrane Protein1 in a subgroup of Patients with EBV-Associated Disease. In: Humoral and Cell-Mediated Immune Responses Directed against Epstein-Barr virus-Encoded Tumor-Associated. Meij P. Enschede :PrintPartner, 1999.
- Meij P. Humoral and Cell-Mediated Immune Responses Directed against Epstein-Barr virus-Encoded Tumor-Associated. Enschede :PrintPartner,2001.
- Paulino AC. Nasopharyngeal Cancer. emedicine, 2004.
- Purba I. Penegakan Diagnosis Immunologik Karsinoma Nasofaring Dengan Pemeriksaan IgA Anti VCA-EBV metode IPA (tesis). Yogyakarta:Univ Gadjah Mada, 1997.
- Roezin A. Berbagai Faktor Penyebab dan Predisposisi Karsinoma Nasofaring. Maj Ked Ind,1999;49(3):85-88.
- Rowe M, Finke J, Szigeti R, Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus.PubMed,1988; 69(Pt 6):1217-28.
- Schantz SP, Harrison LB, Forastiere AA. Tumours of the Nasal Cavity and Oropharynx. In: Cancer,Principles & Practice of Oncology 6th ed.Devit VT, Resenberg SA, Hellman S. Philadelphia: Williams & Wilkins, 2001:824-831.
- Shao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX, Hu LF. Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Pubmed, 2004;24(4):2309-18.
- Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology 10th Ed. New Jersey: John Wiley & sons, 2003.



Wei WI, Sham STJ. Cancer Of Nasopharynx. In: Myets EN, Suen Jy, editor. Cancer of the Head and Neck. Philadelphia:Saunders, 1996: 277-282.

Xu J, Ahmad A, D'Addario M, Knafo L, Jones JF, Prasad U, Dolcetti R, Vaccher E, Menezes J. Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated Diseases. J.Immunol, 2000;164:2815-2822.